COMMUNIQUÉS West-GlobeNewswire

Myriad Genetics Announces Inducement Awards
08/04/2025
SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. [...]
AMN Healthcare to Hold First Quarter 2025 Earnings Conference Call on Thursday, May 8, 2025
08/04/2025
DALLAS, April 08, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its first quarter 2025 financial results and second quarter 2025 outlook on Thursday, May [...]
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025
08/04/2025
PORTLAND, Maine, April 08, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
08/04/2025
Dr. Banerjee’s appointment culminates Artiva’s efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva [...]
Clover Health to Report First Quarter 2025 Financial Results on May 6, 2025
08/04/2025
WILMINGTON, Del., April 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report first quarter 2025 financial results [...]
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities
08/04/2025
SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings [...]
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
08/04/2025
Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease Education Campaign for [...]
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
08/04/2025
NX-5948 assigned the nonproprietary name “bexobrutideg” U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemia Achieved $7M in milestones and a $15M license extension [...]
BON Announces Unlocking Broccoli's Nutritional Power: Advanced Delivery System for Glucoraphanin Activation
08/04/2025
XI’AN, China, April 08, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced [...]
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference
08/04/2025
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual [...]
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
08/04/2025
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people living with non- [...]
Communiqué de presse : Publication dans le NEJM de données de phase III illustrant le bénéfice du tolebrutinib sur la progression du handicap dans la sclérose en plaques
08/04/2025
Publication dans le NEJM de données de phase III illustrant le bénéfice du tolebrutinib sur la progression du handicap dans la sclérose en plaques Les résultats de l’étude de phase III HERCULES montrent que le [...]
EssilorLuxottica: Disclosure of transactions in own shares
08/04/2025
Disclosure of transactions in own shares Paris, France (April 8, 2025 - 6:15 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2024, EssilorLuxottica declares that from [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
08/04/2025
Déclaration de transactions sur actions propres Paris, France (8 avril 2025, 18h15) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2024, EssilorLuxottica déclare que du 3 avril 2025 au 7 [...]
Ipsen publishes its 2024 Universal Registration Document
08/04/2025
Ipsen publishes its 2024 Universal Registration Document PARIS, FRANCE, 8 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the filing of its 2024 Universal Registration Document with the French Autorité [...]
Ipsen publie son Document d’enregistrement universel 2024
08/04/2025
Ipsen publie son Document d’enregistrement universel 2024 PARIS, FRANCE, 8 avril 2025 - Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd’hui que son Document d’enregistrement universel 2024 a été déposé le 7 avril [...]
Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
08/04/2025
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 8 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the [...]
Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of Neurology Annual Meeting
08/04/2025
– EFFICACY : 92% median reduction in disabling seizures during 7-12-month efficacy endpoint period, and 80% (4/5) of patients responding with >75% seizure reduction in Cohort 1. – DURABILITY : All responders (4/4) in [...]
Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting
08/04/2025
CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by neuroinflammation Additional [...]

Pages